--- title: Newsroom | Clinical Research & Trials (3) description: Clinical Research & Trials | (3) --- [![Life Science Newswire 2](https://news.lifesciencenewswire.com/hs-fs/hubfs/Life%20Science%20Newswire%202.png?width=203&height=60&name=Life%20Science%20Newswire%202.png "Life Science Newswire 2")](https://lifesciencenewswire.com/) - [Newsroom](https://news.lifesciencenewswire.com/newsroom) - [Back to the main site](https://lifesciencenewswire.com/) ![LSNewswire-main-header-banner-v2-1](https://news.lifesciencenewswire.com/hubfs/LSNewswire-main-header-banner-v2-1.jpg "LSNewswire-main-header-banner-v2-1") # Newsroom #### Categories ![Arrow](https://cdn2.hubspot.net/hubfs/3842749/ps4-Pack/sidebar.svg "Arrow") #### Subscribe![](https://cdn2.hubspot.net/hubfs/3842749/ps4-Pack/subscribe-rss-button.svg) ![](https://cdn2.hubspot.net/hubfs/3842749/ps4-Pack/close-button.svg) ### Choose a Category - [Agriculture (1)](https://news.lifesciencenewswire.com/newsroom/tag/agriculture) - [AI (1)](https://news.lifesciencenewswire.com/newsroom/tag/ai) - [Analytical Chemistry (42)](https://news.lifesciencenewswire.com/newsroom/tag/analytical-chemistry) - [Biomanufacturing (35)](https://news.lifesciencenewswire.com/newsroom/tag/biomanufacturing) - [biopharma (21)](https://news.lifesciencenewswire.com/newsroom/tag/biopharma) - [Bioprocessing (16)](https://news.lifesciencenewswire.com/newsroom/tag/bioprocessing) - [Biotechnology (251)](https://news.lifesciencenewswire.com/newsroom/tag/biotechnology) - [Cell Culture (10)](https://news.lifesciencenewswire.com/newsroom/tag/cell-culture) - [Clinical Diagnostics (36)](https://news.lifesciencenewswire.com/newsroom/tag/clinical-diagnostics) - [clinical research (6)](https://news.lifesciencenewswire.com/newsroom/tag/clinical-research) - [Clinical Research & Trials (115)](https://news.lifesciencenewswire.com/newsroom/tag/clinical-research-trials) - [Computing & Technology (62)](https://news.lifesciencenewswire.com/newsroom/tag/computing-it) - [Corporate, Finance & Investor (288)](https://news.lifesciencenewswire.com/newsroom/tag/corporate-finance-investor) - [COVID-19 (86)](https://news.lifesciencenewswire.com/newsroom/tag/covid-19) - [Diagnostics & Hospital Laboratory (35)](https://news.lifesciencenewswire.com/newsroom/tag/diagnostics-hospital-laboratory) - [Digital Pathology (1)](https://news.lifesciencenewswire.com/newsroom/tag/digital-pathology) - [Drug Discovery & Development (152)](https://news.lifesciencenewswire.com/newsroom/tag/drug-discovery-development) - [Energy & Environment (15)](https://news.lifesciencenewswire.com/newsroom/tag/energy-environment) - [excipients (1)](https://news.lifesciencenewswire.com/newsroom/tag/excipients) - [Food & Beverage (8)](https://news.lifesciencenewswire.com/newsroom/tag/food-beverage) - [General Chemistry (7)](https://news.lifesciencenewswire.com/newsroom/tag/general-chemistry) - [General Laboratory (58)](https://news.lifesciencenewswire.com/newsroom/tag/general-laboratory) - [General Science (5)](https://news.lifesciencenewswire.com/newsroom/tag/general-science) - [Healthcare (136)](https://news.lifesciencenewswire.com/newsroom/tag/healthcare) - [Hospital Management (7)](https://news.lifesciencenewswire.com/newsroom/tag/hospital-management) - [Life Science (26)](https://news.lifesciencenewswire.com/newsroom/tag/life-science) - [Manufacturing (2)](https://news.lifesciencenewswire.com/newsroom/tag/manufacturing) - [Materials Science (2)](https://news.lifesciencenewswire.com/newsroom/tag/materials-science) - [Medical Devices & Technology (26)](https://news.lifesciencenewswire.com/newsroom/tag/medical-devices-technology) - [Microbiology & Infection Control (18)](https://news.lifesciencenewswire.com/newsroom/tag/microbiology-infection-control) - [Microscopy & Imaging (47)](https://news.lifesciencenewswire.com/newsroom/tag/microscopy-imaging) - [Nanotech (2)](https://news.lifesciencenewswire.com/newsroom/tag/nanotech) - [Omics & Genetics (87)](https://news.lifesciencenewswire.com/newsroom/tag/omics-genetics) - [Pathology (5)](https://news.lifesciencenewswire.com/newsroom/tag/pathology) - [Pharma (118)](https://news.lifesciencenewswire.com/newsroom/tag/pharma) - [Pharmacy (5)](https://news.lifesciencenewswire.com/newsroom/tag/pharmacy) - [Research (47)](https://news.lifesciencenewswire.com/newsroom/tag/research) - [Veterinary (6)](https://news.lifesciencenewswire.com/newsroom/tag/veterinary) - [Water (8)](https://news.lifesciencenewswire.com/newsroom/tag/water) See all ### Subscribe to Email Updates Categories: [Healthcare](https://news.lifesciencenewswire.com/newsroom/tag/healthcare), [COVID-19](https://news.lifesciencenewswire.com/newsroom/tag/covid-19), [Clinical Research & Trials](https://news.lifesciencenewswire.com/newsroom/tag/clinical-research-trials) #### [Groundbreaking myalgic encephalomyelitis study identifies over 250 core genes, shared biology with long COVID, and dozens of drug repurposing opportunities](https://news.lifesciencenewswire.com/newsroom/groundbreaking-myalgic-encephalomyelitis-study-identifies-over-250-core-genes-shared-biology-with-long-covid-and-dozens-of-drug-repurposing-opportunities) December 4, 2025 ##### [READ MORE](https://news.lifesciencenewswire.com/newsroom/groundbreaking-myalgic-encephalomyelitis-study-identifies-over-250-core-genes-shared-biology-with-long-covid-and-dozens-of-drug-repurposing-opportunities) 0 Comments [Click here to read/write comments](https://news.lifesciencenewswire.com/newsroom/groundbreaking-myalgic-encephalomyelitis-study-identifies-over-250-core-genes-shared-biology-with-long-covid-and-dozens-of-drug-repurposing-opportunities#comments-listing) by [Life Science Newswire](https://news.lifesciencenewswire.com/newsroom/author/newswire) on Dec 4, 2025, 9:09:27 AM - [Tweet](https://twitter.com/share) Categories: [Biomanufacturing](https://news.lifesciencenewswire.com/newsroom/tag/biomanufacturing), [Clinical Research & Trials](https://news.lifesciencenewswire.com/newsroom/tag/clinical-research-trials) #### [Lonza expands its TheraPEAK® product portfolio with the addition of AmpliCell® Cytokine range and TheraPEAK® 293-GT® Medium](https://news.lifesciencenewswire.com/newsroom/lonza-expands-its-therapeak-product-portfolio-with-the-addition-of-amplicell-cytokine-range-and-therapeak-293-gt-medium) October 6, 2025 ##### [READ MORE](https://news.lifesciencenewswire.com/newsroom/lonza-expands-its-therapeak-product-portfolio-with-the-addition-of-amplicell-cytokine-range-and-therapeak-293-gt-medium) 0 Comments [Click here to read/write comments](https://news.lifesciencenewswire.com/newsroom/lonza-expands-its-therapeak-product-portfolio-with-the-addition-of-amplicell-cytokine-range-and-therapeak-293-gt-medium#comments-listing) by [Life Science Newswire](https://news.lifesciencenewswire.com/newsroom/author/newswire) on Oct 6, 2025, 1:05:16 PM - [Tweet](https://twitter.com/share) Categories: [Omics & Genetics](https://news.lifesciencenewswire.com/newsroom/tag/omics-genetics), [Biotechnology](https://news.lifesciencenewswire.com/newsroom/tag/biotechnology), [Drug Discovery & Development](https://news.lifesciencenewswire.com/newsroom/tag/drug-discovery-development), [Pharma](https://news.lifesciencenewswire.com/newsroom/tag/pharma), [Clinical Research & Trials](https://news.lifesciencenewswire.com/newsroom/tag/clinical-research-trials) #### [EpiCypher launches Fiber-seq, a breakthrough multiomic single-molecule genomics assay](https://news.lifesciencenewswire.com/newsroom/epicypher-launches-fiber-seq-a-breakthrough-multiomic-single-molecule-genomics-assay) September 3, 2025 ##### [READ MORE](https://news.lifesciencenewswire.com/newsroom/epicypher-launches-fiber-seq-a-breakthrough-multiomic-single-molecule-genomics-assay) 0 Comments [Click here to read/write comments](https://news.lifesciencenewswire.com/newsroom/epicypher-launches-fiber-seq-a-breakthrough-multiomic-single-molecule-genomics-assay#comments-listing) by [Life Science Newswire](https://news.lifesciencenewswire.com/newsroom/author/newswire) on Sep 3, 2025, 3:15:00 PM - [Tweet](https://twitter.com/share) Categories: [Pharma](https://news.lifesciencenewswire.com/newsroom/tag/pharma), [Clinical Research & Trials](https://news.lifesciencenewswire.com/newsroom/tag/clinical-research-trials) #### [Friends of Cancer Research and MMS collaborate to develop decision frameworks for interim overall survival data in oncology trials](https://news.lifesciencenewswire.com/newsroom/friends-of-cancer-research-and-mms-collaborate-to-develop-decision-frameworks-for-interim-overall-survival-data-in-oncology-trials) August 20, 2025 ##### [READ MORE](https://news.lifesciencenewswire.com/newsroom/friends-of-cancer-research-and-mms-collaborate-to-develop-decision-frameworks-for-interim-overall-survival-data-in-oncology-trials) 0 Comments [Click here to read/write comments](https://news.lifesciencenewswire.com/newsroom/friends-of-cancer-research-and-mms-collaborate-to-develop-decision-frameworks-for-interim-overall-survival-data-in-oncology-trials#comments-listing) by [Life Science Newswire](https://news.lifesciencenewswire.com/newsroom/author/newswire) on Aug 20, 2025, 12:00:00 PM - [Tweet](https://twitter.com/share) Categories: [Healthcare](https://news.lifesciencenewswire.com/newsroom/tag/healthcare), [Clinical Research & Trials](https://news.lifesciencenewswire.com/newsroom/tag/clinical-research-trials) #### [Duke Street Bio receives FDA Fast Track designation for PARP1-Selective Inhibitor DSB2455 in patients with HRD brain metastases from triple-negative breast cancer](https://news.lifesciencenewswire.com/newsroom/duke-street-bio-receives-fda-fast-track-designation-for-parp1-selective-inhibitor-dsb2455-in-patients-with-hrd-brain-metastases-from-triple-negative-breast-cancer) June 16, 2025 ##### [READ MORE](https://news.lifesciencenewswire.com/newsroom/duke-street-bio-receives-fda-fast-track-designation-for-parp1-selective-inhibitor-dsb2455-in-patients-with-hrd-brain-metastases-from-triple-negative-breast-cancer) 0 Comments [Click here to read/write comments](https://news.lifesciencenewswire.com/newsroom/duke-street-bio-receives-fda-fast-track-designation-for-parp1-selective-inhibitor-dsb2455-in-patients-with-hrd-brain-metastases-from-triple-negative-breast-cancer#comments-listing) by [Life Science Newswire](https://news.lifesciencenewswire.com/newsroom/author/newswire) on Jun 16, 2025, 12:30:00 PM - [Tweet](https://twitter.com/share) Categories: [Bioprocessing](https://news.lifesciencenewswire.com/newsroom/tag/bioprocessing), [Clinical Research & Trials](https://news.lifesciencenewswire.com/newsroom/tag/clinical-research-trials), [Corporate, Finance & Investor](https://news.lifesciencenewswire.com/newsroom/tag/corporate-finance-investor) #### [Biofidelity and CellCarta partner to deploy Aspyre® Lung in global clinical trials](https://news.lifesciencenewswire.com/newsroom/biofidelity-and-cellcarta-partner-to-deploy-aspyre-lung-in-global-clinical-trials) January 9, 2025 ##### [READ MORE](https://news.lifesciencenewswire.com/newsroom/biofidelity-and-cellcarta-partner-to-deploy-aspyre-lung-in-global-clinical-trials) 0 Comments [Click here to read/write comments](https://news.lifesciencenewswire.com/newsroom/biofidelity-and-cellcarta-partner-to-deploy-aspyre-lung-in-global-clinical-trials#comments-listing) by [Life Science Newswire](https://news.lifesciencenewswire.com/newsroom/author/newswire) on Jan 9, 2025, 2:30:00 PM - [Tweet](https://twitter.com/share) Categories: [Healthcare](https://news.lifesciencenewswire.com/newsroom/tag/healthcare), [Clinical Research & Trials](https://news.lifesciencenewswire.com/newsroom/tag/clinical-research-trials), [Corporate, Finance & Investor](https://news.lifesciencenewswire.com/newsroom/tag/corporate-finance-investor) #### [ENEA-Tech Biomedical Foundation invests €6m in BetaGlue® Therapeutics brings 2024 funding round total to €24m](https://news.lifesciencenewswire.com/newsroom/enea-tech-biomedical-foundation-invests-6m-in-betaglue-therapeutics-brings-2024-funding-round-total-to-24m) December 16, 2024 ##### [READ MORE](https://news.lifesciencenewswire.com/newsroom/enea-tech-biomedical-foundation-invests-6m-in-betaglue-therapeutics-brings-2024-funding-round-total-to-24m) 0 Comments [Click here to read/write comments](https://news.lifesciencenewswire.com/newsroom/enea-tech-biomedical-foundation-invests-6m-in-betaglue-therapeutics-brings-2024-funding-round-total-to-24m#comments-listing) by [Life Science Newswire](https://news.lifesciencenewswire.com/newsroom/author/newswire) on Dec 16, 2024, 1:30:00 PM - [Tweet](https://twitter.com/share) Categories: [Healthcare](https://news.lifesciencenewswire.com/newsroom/tag/healthcare), [Clinical Research & Trials](https://news.lifesciencenewswire.com/newsroom/tag/clinical-research-trials) #### [Ceryx Medical initiates first-in-human study of the Cysoni™ RSA Pacemaker](https://news.lifesciencenewswire.com/newsroom/ceryx-medical-initiates-first-in-human-study-of-the-cysoni-rsa-pacemaker) December 9, 2024 ##### [READ MORE](https://news.lifesciencenewswire.com/newsroom/ceryx-medical-initiates-first-in-human-study-of-the-cysoni-rsa-pacemaker) 0 Comments [Click here to read/write comments](https://news.lifesciencenewswire.com/newsroom/ceryx-medical-initiates-first-in-human-study-of-the-cysoni-rsa-pacemaker#comments-listing) by [Life Science Newswire](https://news.lifesciencenewswire.com/newsroom/author/newswire) on Dec 9, 2024, 12:00:00 PM - [Tweet](https://twitter.com/share) Categories: [Biotechnology](https://news.lifesciencenewswire.com/newsroom/tag/biotechnology), [Clinical Research & Trials](https://news.lifesciencenewswire.com/newsroom/tag/clinical-research-trials) #### [Duke Street Bio announces first patient dosed in Phase I trial with DSB2455, a next deneration PARP1 selective inhibitor for the treatment of solid tumours](https://news.lifesciencenewswire.com/newsroom/duke-street-bio-announces-first-patient-dosed-in-phase-i-trial-with-dsb2455-a-next-deneration-parp1-selective-inhibitor-for-the-treatment-of-solid-tumours) December 3, 2024 ##### [READ MORE](https://news.lifesciencenewswire.com/newsroom/duke-street-bio-announces-first-patient-dosed-in-phase-i-trial-with-dsb2455-a-next-deneration-parp1-selective-inhibitor-for-the-treatment-of-solid-tumours) 0 Comments [Click here to read/write comments](https://news.lifesciencenewswire.com/newsroom/duke-street-bio-announces-first-patient-dosed-in-phase-i-trial-with-dsb2455-a-next-deneration-parp1-selective-inhibitor-for-the-treatment-of-solid-tumours#comments-listing) by [Life Science Newswire](https://news.lifesciencenewswire.com/newsroom/author/newswire) on Dec 3, 2024, 10:00:00 AM - [Tweet](https://twitter.com/share) [Previous](https://news.lifesciencenewswire.com/newsroom/tag/clinical-research-trials/page/2) [All posts](https://news.lifesciencenewswire.com/newsroom/all) [Next](https://news.lifesciencenewswire.com/newsroom/tag/clinical-research-trials/page/4) ##### Browse more news ## Recent releases #### [CellCarta and Imagene AI Expand Collaboration to Validate, Deploy and Scale AI-Powered Biomarker and...](https://news.lifesciencenewswire.com/newsroom/cellcarta-and-imagene-ai-expand-collaboration-to-validate-deploy-and-scale-ai-powered-biomarker-and-companion-diagnostic-programs-across-drug-development) October 1, 2026 The collaboration combines Imagene’s AI-powered assay development and biomarker prediction capabilities with CellCarta’s global companion diagnostics ... ##### [READ MORE](https://news.lifesciencenewswire.com/newsroom/cellcarta-and-imagene-ai-expand-collaboration-to-validate-deploy-and-scale-ai-powered-biomarker-and-companion-diagnostic-programs-across-drug-development) #### [Ceryx Medical appoints Professor Zaheer Yousef OBE as Chief Medical Officer](https://news.lifesciencenewswire.com/newsroom/ceryx-medical-appoints-professor-zaheer-yousef-obe-as-chief-medical-officer) September 21, 2026 Leading heart failure cardiologist and RSA-Pace principal investigator joins as the company prepares its next clinical study Ceryx Medical (Ceryx), th... ##### [READ MORE](https://news.lifesciencenewswire.com/newsroom/ceryx-medical-appoints-professor-zaheer-yousef-obe-as-chief-medical-officer) #### [Qinecsa selected as technology partner for Africa’s new continent-wide medicines safety platform](https://news.lifesciencenewswire.com/newsroom/qinecsa-selected-as-technology-partner-for-africas-new-continent-wide-medicines-safety-platform) September 10, 2026 The global pharmacovigilance specialist will help drive one of Africa’s most comprehensive medicines safety initiatives. Qinecsa, the global pharmacov... ##### [READ MORE](https://news.lifesciencenewswire.com/newsroom/qinecsa-selected-as-technology-partner-for-africas-new-continent-wide-medicines-safety-platform) ![LS-Newswire-reverse](https://news.lifesciencenewswire.com/hs-fs/hubfs/raw_assets/public/LifeScienceNewswire_June2020/images/LS-Newswire-reverse.png?width=150&name=LS-Newswire-reverse.png "LS-Newswire-reverse") Life Science Newswire is a division of BioStrata Ltd, with company registered address: 3rd Floor, 1 Ashley Road, Altrincham, Cheshire, England, WA14 2DT. Company registration number: 8233225  #### Useful information - [Cookie and privacy policy](https://lifesciencenewswire.com/cookie-privacy-policy/) - [Website terms and conditions](https://lifesciencenewswire.com/terms-and-conditions) - [Promotion terms and conditions](https://lifesciencenewswire.com/promotion_terms/)